3-乙氧基-6-(3-甲基丁基)-2-环己烯-1-酮 | 147120-45-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-乙氧基-6-(3-甲基丁基)-2-环己烯-1-酮
• 英文名称: 3-Ethoxy-6-isopentyl-2-cyclohexen-1-one
• 英文别名: 3-ethoxy-6-(3-methyl-butyl)cyclohex-2-enone；3-Ethoxy-6-(3-methylbutyl)cyclohex-2-en-1-one
• CAS: 147120-45-4
• 化学式: C₁₃H₂₂O₂
• 分子量: 210.316
• InChiKey: NZYNNZZTNABFCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-乙氧基-6-(3-甲基丁基)-2-环己烯-1-酮 在 potassium tert-butylate 、 二异丁基氢化铝 、 potassium carbonate 、 甲烷 作用下， 以 四氢呋喃 、 5,5-dimethyl-1,3-cyclohexadiene 、 水 、 甲苯 为溶剂， 反应 8.5h， 生成 tert-butyl (3S)-3-[7-(3-methylbutyl)-4-methylidene-6,7-dihydro-5H-1,2-benzoxazol-3-yl]-6-phenylmethoxyhexanoate
  参考文献：
  名称：

  TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF

  摘要：

  由式[I]表示的化合物： 或其药学上可接受的盐，其中每个符号如描述中所定义。

  公开号：

  US20160137639A1
• 作为产物：
  描述：

  异戊基碘 、 3-乙氧基-2-环己烯-1-酮 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以3.68 g的产率得到3-乙氧基-6-(3-甲基丁基)-2-环己烯-1-酮
  参考文献：
  名称：

  TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF

  摘要：

  由式[I]表示的化合物： 或其药学上可接受的盐，其中每个符号如描述中所定义。

  公开号：

  US20160137639A1

文献信息

• [EN] TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF<br/>[FR] COMPOSÉ TRIAZOLE-ISOXAZOLE ET UTILISATION MÉDICALE DE CELUI-CI
  申请人：JAPAN TOBACCO INC

  公开号：WO2014065413A1

  公开（公告）日：2014-05-01

  　下記一般式［Ｉ］で表される化合物又はその医薬上許容される塩。（式中、各記号は明細書に記載の通りである。）
• TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF
  申请人：JAPAN TOBACCO INC.

  公开号：US20160137639A1

  公开（公告）日：2016-05-19

  A compound represented by Formula [I]: or pharmaceutically acceptable salt thereof, wherein each symbol is as defined in the description.

  由式[I]表示的化合物： 或其药学上可接受的盐，其中每个符号如描述中所定义。
• New approaches to the synthesis of alkyl-substituted enol lactone systems, inhibitors of the serine protease elastase
  作者：Wei Dai、John A. Katzenellenbogen

  DOI：10.1021/jo00059a049

  日期：1993.3

  We have synthesized a series of alkyl-substituted enol lactones designed to act as mechanism-based inhibitors of human neutrophil elastase (HLE). General methods were developed for the preparation of alpha- and beta-alkyl-substituted 5-hexynoic acids by the bromoform reaction on the corresponding alkynoic methyl ketone, prepared by an Eschenmoser-Tanabe fragmentation sequence from a suitably substituted cyclohexenone. By this method, beta-methyl- and beta,beta-dimethyl-5-hexynoic acids were synthesized from commercially available isophorone and 3,5-dimethyl-2-cyclohexen-1-one, respectively. Alpha-Substituted 5-hexynoic acids were prepared from 3-ethoxy-2-cyclohexen-1-one, using a novel ZnCl2-mediated alkylation that we developed; this method gives high yields of alpha'-alkylation products, even with secondary halides. The most efficient method for the preparation of alpha-substituted 5-hexynoic acids involved a four-reaction sequence-alkylation of the alpha-substituted ester with 1,4-dibromobutane, elimination, bromination and bisdehydrobromination-that proceeded in high overall yield. Protio enol lactonizations were performed with mercury(II) catalysis in CH2Cl2 or CH2Cl2-H2O. Stereo-selective Z-bromo enol lactonization was carried out by Br+-induced lactonization in the presence of Ag+. E-Bromo enol lactonization with N-bromosuccinimide in CH2Cl2 in the presence of a small amount of water gave better yields and shorter reaction times than the traditional anhydrous conditions. In studies of the inhibitory activity of these lactones toward several proteases (reported in full elsewhere), we found that the alpha-alkyl-substituted protio and bromo enol lactones 1-3 were very good inhibitors of HLE, with k(a)/K(i) values ranging from 14 500 to 37 500 M-1 s-1; the beta-alkyl-substituted enol lactones 5-8 showed only moderate inhibition of HLE.